Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Saniona publishes its year-end report for 2020
Saniona ABMarch 17, 2021 GMT
PRESS RELEASE Revenue was SEK 8.2 M (7.2 M) Operating loss was SEK -159.4 (-93.6 M) Net loss was SEK -73.4 M (-68.8 M) Earnings per share were SEK -1.79 (-2.67) Diluted earnings per share were SEK -1.75 (-2.67)
Q4 2020 (Q4 2019 restated) Revenue was SEK 1.6 M (0.0 M) Operating loss was SEK -68.8 M (-28.2 M) Net loss was SEK -45.6 M (-6.8 M) Earnings per share were SEK -0.73 (-0.24) Diluted earnings per share were SEK -0.73 (-0.24)
Boston
Massachusetts
United-states
Denmark
Copenhagen
Køavn
Stockholm
Sweden
Trista-morrison
University-of-pennsylvania
Boehringer-ingelheim
Drug-administration
Saniona AB: Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity
March 8, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received feedback from the U.S. Food and Drug Administration (FDA) providing further clarity on a regulatory path for Tesomet in the treatment of hypothalamic obesity (HO). Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year. There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger, said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase
Stockholm
Sweden
Boston
Massachusetts
United-states
Denmark
Copenhagen
Køavn
Trista-morrison
Rudolf-baumgartner
Head-of-clinical-development-at-saniona
Drug-administration